Attached files
| file | filename |
|---|---|
| EX-10.14 - EX-10.14 - Seres Therapeutics, Inc. | mcrb-ex1014_439.htm |
| EX-10.19 - EX-10.19 - Seres Therapeutics, Inc. | mcrb-ex1019_440.htm |
| EX-32.2 - EX-32.2 - Seres Therapeutics, Inc. | mcrb-ex322_7.htm |
| EX-32.1 - EX-32.1 - Seres Therapeutics, Inc. | mcrb-ex321_9.htm |
| EX-31.2 - EX-31.2 - Seres Therapeutics, Inc. | mcrb-ex312_8.htm |
| EX-31.1 - EX-31.1 - Seres Therapeutics, Inc. | mcrb-ex311_11.htm |
| EX-10.11 - EX-10.11 - Seres Therapeutics, Inc. | mcrb-ex1011_438.htm |
| EX-10.8 - EX-10.8 - Seres Therapeutics, Inc. | mcrb-ex108_441.htm |
| 10-K - 10-K - Seres Therapeutics, Inc. | mcrb-10k_20171231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (No. 333-205253 and 333-210171) and Form S-3 (No. 333-216735) of Seres Therapeutics, Inc. of our report dated March 8, 2018 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 8, 2018